{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:51:54Z","timestamp":1740135114752,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01"],"award-info":[{"award-number":["1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01","1OT2HL156812-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Assessment for risks associated with acute stable COVID-19 is important to optimize clinical trial enrollment and target patients for scarce therapeutics. To assess whether healthcare system engagement location is an independent predictor of outcomes we performed a secondary analysis of the ACTIV-4B Outpatient Thrombosis Prevention trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A secondary analysis of the ACTIV-4B trial that was conducted at 52 US sites between September 2020 and August 2021. Participants were enrolled through acute unscheduled episodic care (AUEC) enrollment location (emergency department, or urgent care clinic visit) compared to minimal contact (MC) enrollment (electronic contact from test center lists of positive patients).We report the primary composite outcome of cardiopulmonary hospitalizations, symptomatic venous thromboembolism, myocardial infarction, stroke, transient ischemic attack, systemic arterial thromboembolism, or death among stable outpatients stratified by enrollment setting, AUEC versus MC. A propensity score for AUEC enrollment was created, and Cox proportional hazards regression with inverse probability weighting (IPW) was used to compare the primary outcome by enrollment location.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 657 ACTIV-4B patients randomized, 533 (81.1%) with known enrollment setting data were included in this analysis, 227 from AUEC settings and 306 from MC settings. In a multivariate logistic regression model, time from COVID test, age, Black race, Hispanic ethnicity, and body mass index were associated with AUEC enrollment. Irrespective of trial treatment allocation, patients enrolled at an AUEC setting were 10-times more likely to suffer from the adjudicated primary outcome, 7.9% vs. 0.7%; p\u2009&lt;\u20090.001, compared with patients enrolled at a MC setting. Upon Cox regression analysis adjustment patients enrolled at an AUEC setting remained at significant risk of the primary composite outcome, HR 3.40 (95% CI 1.46, 7.94).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with clinically stable COVID-19 presenting to an AUEC enrollment setting represent a population at increased risk of arterial and venous thrombosis complications, hospitalization for cardiopulmonary events, or death, when adjusted for other risk factors, compared with patients enrolled at a MC setting. Future outpatient therapeutic trials and clinical therapeutic delivery programs of clinically stable COVID-19 patients may focus on inclusion of higher-risk patient populations from AUEC engagement locations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial Registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov Identifier: NCT04498273.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08295-9","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:39:02Z","timestamp":1684161542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinically stable covid-19 patients presenting to acute unscheduled episodic care venues have increased risk of hospitalization: secondary analysis of a randomized control trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Joseph","family":"Bledsoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott C.","family":"Woller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank C.","family":"Sciurba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry A.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrei","family":"Kindzelski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen","family":"Handberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget-Anne","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Zaharris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Majercik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuxuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidya","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hsuan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"8295_CR1","unstructured":"World Health Organization. https:\/\/covid19.who.int. Accessed on Nov. 1, 2021."},{"key":"8295_CR2","doi-asserted-by":"crossref","unstructured":"Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and Cardiac Pathology in Covid-19: the first autopsy Series from New Orleans. medRxiv. 2020. 2020.04.06.20050575.","DOI":"10.1101\/2020.04.06.20050575"},{"issue":"19","key":"8295_CR3","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1093\/eurheartj\/ehaa254","volume":"41","author":"GB Danzi","year":"2020","unstructured":"Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur. Heart J. 2020;41(19):1858.","journal-title":"Heart J"},{"key":"8295_CR4","doi-asserted-by":"publisher","DOI":"10.7326\/m20-2003","author":"D Wichmann","year":"2020","unstructured":"Wichmann D, Sperhake JP, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/m20-2003.","journal-title":"Ann Intern Med"},{"key":"8295_CR5","unstructured":"Liu Q, Wang RS, Qu GQ et al. Gross examination report of a COVID-19 death autopsy, Fa yi xue za zhi 36 (2020) 21\u20133."},{"key":"8295_CR6","first-page":"E040","volume":"43","author":"T Zhang","year":"2020","unstructured":"Zhang T, Sun LX, Feng RE. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin. J Tuberc Respir Dis. 2020;43:E040.","journal-title":"J Tuberc Respir Dis"},{"key":"8295_CR7","doi-asserted-by":"crossref","unstructured":"Xu J-F, Wang L, Zhao L et al. Risk Assessment of Venous Thromboembolism and Bleeding in COVID-19 Patients, Research Square, 2020.","DOI":"10.21203\/rs.3.rs-18340\/v1"},{"key":"8295_CR8","doi-asserted-by":"publisher","unstructured":"Poissy J, Goutay J, Caplan M et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence, Circulation (2020), https:\/\/doi.org\/10.1161\/circulationaha.120.047430.","DOI":"10.1161\/circulationaha.120.047430"},{"key":"8295_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.013","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb. Res. 2020. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.013.","journal-title":"Res"},{"key":"8295_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.041","author":"FA Klok","year":"2020","unstructured":"Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020. https:\/\/doi.org\/10.1016\/j.thromres.2020.04.041.","journal-title":"Thromb Res"},{"key":"8295_CR11","doi-asserted-by":"crossref","unstructured":"Middeldorp S, Coppens M, van Haaps TF et al. Incidence of Venous Thromboembolism in Hospitalized Patients with COVID-19, 2020040345 Preprints, 2020.","DOI":"10.20944\/preprints202004.0345.v1"},{"key":"8295_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","volume":"191","author":"C Lodigiani","year":"2020","unstructured":"Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9\u201314.","journal-title":"Thromb Res"},{"key":"8295_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.thromres.2020.05.031","volume":"192","author":"R Emert","year":"2020","unstructured":"Emert R, Shah P, Zampella JG. COVID-19 and hypercoagulability in the outpatient setting. Thromb Res. 2020;192:122\u20133. https:\/\/doi.org\/10.1016\/j.thromres.2020.05.031.","journal-title":"Thromb Res"},{"key":"8295_CR14","doi-asserted-by":"publisher","unstructured":"Connors JM, Brooks MM, Sciurba FC et al. Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients with Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA.2021;326(17):1703\u20131712. doi:https:\/\/doi.org\/10.1001\/jama.2021.17272.","DOI":"10.1001\/jama.2021.17272"},{"key":"8295_CR15","doi-asserted-by":"crossref","unstructured":"Lenze EJ, Mattar C, Zorumski CF et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA 2020 Dec 8;324(22):2292\u2013300.","DOI":"10.1001\/jama.2020.22760"},{"key":"8295_CR16","doi-asserted-by":"publisher","unstructured":"Daniel P, Shirley S, Jatinder SM et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review, EClinicalMedicine, Vol. 23, 2020, 100404, ISSN 2589\u20135370, https:\/\/doi.org\/10.1016\/j.eclinm.2020.100404.","DOI":"10.1016\/j.eclinm.2020.100404"},{"key":"8295_CR17","doi-asserted-by":"publisher","unstructured":"Krithi R. Ethnic disparities in COVID-19 mortality: are comorbidities to blame? The Lancet, Vol.\u00a0396, Issue 10243, 2020, Page 22, ISSN 0140\u20136736, https:\/\/doi.org\/10.1016\/S0140-6736(20)31423-9.","DOI":"10.1016\/S0140-6736(20)31423-9"},{"key":"8295_CR18","doi-asserted-by":"publisher","first-page":"e048006","DOI":"10.1136\/bmjopen-2020-048006","volume":"11","author":"Z Xian","year":"2021","unstructured":"Xian Z, Saxena A, Javed Z, et al. COVID-19-related state-wise racial and ethnic disparities across the USA: an observational study based on publicly available data from the COVID Tracking Project. BMJ Open. 2021;11:e048006. https:\/\/doi.org\/10.1136\/bmjopen-2020-048006.","journal-title":"BMJ Open"},{"key":"8295_CR19","doi-asserted-by":"publisher","unstructured":"Theresa Andrasfay N, Goldman. Reductions in 2020 US life expectancy due to COVID-19 and the disproportionate impact on the Black and Latino populations, Proceedings of the National Academy of Sciences Feb. 2021, 118 (5) e2014746118; DOI:https:\/\/doi.org\/10.1073\/pnas.2014746118.","DOI":"10.1073\/pnas.2014746118"},{"key":"8295_CR20","doi-asserted-by":"publisher","unstructured":"Webb Hooper M, Napoles AM, P\u00e9rez-Stable EJ. COVID-19 and Racial\/Ethnic Disparities. JAMA.2020;323(24):2466\u20132467. doi:https:\/\/doi.org\/10.1001\/jama.2020.8598.","DOI":"10.1001\/jama.2020.8598"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08295-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:41:55Z","timestamp":1684161715000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08295-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8295"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08295-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol, informed consent documents and statistical analysis plan were approved by the Western Institutional Review Board (WIRB) acting as the central single IRB. Patients enrolled in the trial provided written informed consent for participation and all research involving human participants, human material, or human data, was performed in accordance with the Declaration of Helsinki and was approved by an appropriate ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JRB reported receiving grants payable his institution from the National Institutes of Health (NIH) for clinical trial work and receiving consulting fees from JAJ LLC. JMC reported receiving personal fees from Bristol Myers Squibb, Pfizer, Abbott, Alnylam, Takeda, Roche, and Sanofi and that his institution has received research funding from CSL Behring. MB reported receiving personal fees for data and safety monitoring board membership from Cerus Corporation. JAK reported receiving consulting fees from GlaxoSmithKline and research funding from Sergey Brin Family Foundation, National Institutes of Health, American Lung Association, and the Patient Centered Outcomes Research Institute. BK reported receiving grants from SOCAR Research SA. PH reported receiving grants from Brigham and Women\u2019s Hospital, NIH, Novartis, and CalciMedica. PMR reported receiving grants from Bristol Myers Squibb and Pfizer and serving as a consultant for work unrelated to this study for Corvidia, Novartis, Flame, Agepha, Inflazome, AstraZeneca, Janssen, Civi Biopharm, SOCAR, Novo Nordisk, Uptton, Omeicos, and Boehringer Ingelheim. No other authors reported disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}